Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia
Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other...
Saved in:
| Main Authors: | Xiaoshuai Zhang, Yunfan Yang, Bingcheng Liu, Xin Du, Xiaodong Wang, Huanling Zhu, Lu Yu, Zongru Li, Shasha Zhao, Linhua Yang, Yanping Ma, Li Meng, Yanqing Zhang, Guohui Li, Lijie Yang, Baohong Wang, Xuehong Ran, Jian Huang, Na Gao, Qin Wen, Yan Wen, Yuxia Zhao, Yu Zhu, Yanqiu Han, Zhenfang Liu, Jianyu Weng, Robert Peter Gale, Li Zhou, Yanli Zhang, Qian Jiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-04-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Olverembatinib in chronic myeloid leukemia: is less actually better?
by: Maria Agustina Perusini, et al.
Published: (2025-06-01) -
Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells
by: Jia-Hua Zhang, et al.
Published: (2017-06-01) -
The role of microbiota in the chronic prostatitis/chronic pelvis pain syndrome: a review
by: An-Qi Deng, et al.
Published: (2025-03-01) -
Associations between skeletal muscle strength and chronic kidney disease in patients with MASLD
by: Xin-Lei Zhang, et al.
Published: (2025-04-01) -
Role of magnesium in chronic kidney disease complications
by: Long Meng-tuan, et al.
Published: (2021-01-01)